| Schedule of Financial Information Operating Segment |
The
following table presents selected financial information with respect to the Company’s single operating segment and its significant
segment expenses for the years ended June 30, 2025 and 2024:
Schedule
of Financial Information Operating Segment
| |
|
2025 |
|
|
2024 |
|
| |
|
June 30, |
|
| |
|
2025 |
|
|
2024 |
|
| Pre-clinical and clinical studies |
|
$ |
1,842,209 |
|
|
$ |
1,668,780 |
|
| Contract manufacturing |
|
|
1,196,728 |
|
|
|
795,134 |
|
| Consultants and other research and development |
|
|
1,261,004 |
|
|
|
1,085,023 |
|
| Compensation and related benefits |
|
|
1,403,200 |
|
|
|
1,733,032 |
|
| Professional and consultant fees |
|
|
1,291,557 |
|
|
|
1,526,442 |
|
| Stock-based compensation expense |
|
|
1,446,824 |
|
|
|
758,884 |
|
| Directors’ and officers’ insurance |
|
|
497,748 |
|
|
|
469,855 |
|
| Facilities, fees and other related costs |
|
|
284,211 |
|
|
|
271,605 |
|
| Interest expense |
|
|
382,014 |
|
|
|
151,230 |
|
| Interest income |
|
|
(257,913 |
) |
|
|
(249,022 |
) |
| Grant income |
|
|
(864,014 |
) |
|
|
- |
|
| Other |
|
|
1,195 |
|
|
|
(9,260 |
) |
| Net loss |
|
$ |
(8,484,763 |
) |
|
$ |
(8,201,703 |
) |
|